VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

ΔureC hly+ rBCG
Vaccine Information
  • Vaccine Name: ΔureC hly+ rBCG
  • Target Pathogen: Mycobacterium tuberculosis
  • Target Disease: Tuberculosis
  • Vaccine Ontology ID: VO_0000606
  • Type: Live, attenuated vaccine
  • Status: Research
  • Preparation: In order to generate a live vaccine that provides improved protection against M. tuberculosis, BCG was equipped with the membrane-perforating Hly of L. monocytogenes (hly+ rBCG). To improve the pH milieu for Hly activity, a ΔureC hly+ rBCG strain that lacked ureC activity was constructed (Grode et al., 2005).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Cattle Response

  • Vaccination Protocol: Mice were immunized i.v. with 106 CFU of BCG strains (Grode et al., 2005).
  • Challenge Protocol: At 120 days after vaccination, animals were aerosol challenged with 100–200 CFU of M. tuberculosis H37Rv or Beijing/W per lung using an aerosol chamber (Glas-Col) (Grode et al., 2005).
  • Efficacy: The ΔureC hly+ rBCG vaccine strain induced significantly more efficacious in inducing protective immunity against 2 different M. tuberculosis strains, the laboratory strain H37Rv and a clinical isolate of the Beijing/W genotype family, in a mouse model, than parental BCG (Grode et al., 2005). The ΔureC hly+ rBCG vaccine provided even more efficient protection than the hly+ rBCG vaccine strain.
References
Grode et al., 2005: Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, Mann P, Goosmann C, Bandermann S, Smith D, Bancroft GJ, Reyrat JM, van Soolingen D, Raupach B, Kaufmann SH. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. The Journal of clinical investigation. 2005; 115(9); 2472-2479. [PubMed: 16110326].